-
1
-
-
0032077205
-
Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study
-
Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69 (1998) 103-108
-
(1998)
Gynecol. Oncol.
, vol.69
, pp. 103-108
-
-
Eisenkop, S.M.1
Friedman, R.L.2
Wang, H.J.3
-
2
-
-
9744223515
-
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma
-
Vasey P.A., Jayson G.C., Gordon A., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 (2004) 1682-1691
-
(2004)
J. Natl. Cancer Inst.
, vol.96
, pp. 1682-1691
-
-
Vasey, P.A.1
Jayson, G.C.2
Gordon, A.3
-
3
-
-
0141688377
-
Gynecologic oncology group. phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study
-
Ozols R.F., Bundy B.N., Greer B.E., et al. Gynecologic oncology group. phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 21 (2003) 3194-3200
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 3194-3200
-
-
Ozols, R.F.1
Bundy, B.N.2
Greer, B.E.3
-
4
-
-
4644225190
-
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
-
Gordon A.N., Tonda M., Sun S., et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol. 95 (2004) 1-8
-
(2004)
Gynecol. Oncol.
, vol.95
, pp. 1-8
-
-
Gordon, A.N.1
Tonda, M.2
Sun, S.3
-
5
-
-
0037862963
-
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
-
Parmar M.K., Ledermann J.A., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
-
(2003)
Lancet
, vol.361
, pp. 2099-2106
-
-
Parmar, M.K.1
Ledermann, J.A.2
Colombo, N.3
-
6
-
-
7444240809
-
Critical evaluation of secondary cytoreduction in recurrent ovarian cancer
-
Munkarah A.R., and Coleman R.L. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol. Oncol. 95 (2004) 273-280
-
(2004)
Gynecol. Oncol.
, vol.95
, pp. 273-280
-
-
Munkarah, A.R.1
Coleman, R.L.2
-
7
-
-
0036498788
-
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis
-
Bristow R.E., Tomacruz R.S., Armstrong D.K., et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002) 1248-1259
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 1248-1259
-
-
Bristow, R.E.1
Tomacruz, R.S.2
Armstrong, D.K.3
-
8
-
-
0027513786
-
Secondary cytoreduction for ovarian cancer following cisplatin therapy
-
Segna R.A., Dottino P.R., Mandeli J.P., et al. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J. Clin. Oncol. 11 (1993) 434-439
-
(1993)
J. Clin. Oncol.
, vol.11
, pp. 434-439
-
-
Segna, R.A.1
Dottino, P.R.2
Mandeli, J.P.3
-
9
-
-
0033957510
-
The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma
-
Eisenkop S.M., Friedman R.L., and Spirtos N.M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88 (2000) 144-153
-
(2000)
Cancer
, vol.88
, pp. 144-153
-
-
Eisenkop, S.M.1
Friedman, R.L.2
Spirtos, N.M.3
-
10
-
-
1542344369
-
Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?
-
Zang R.Y., Li Z.T., Tang J., et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?. Cancer 100 (2004) 1152-1161
-
(2004)
Cancer
, vol.100
, pp. 1152-1161
-
-
Zang, R.Y.1
Li, Z.T.2
Tang, J.3
-
11
-
-
0024439661
-
Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
-
Morris M., Gershenson D.M., Wharton J.T., et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol. Oncol. 34 (1989) 334-338
-
(1989)
Gynecol. Oncol.
, vol.34
, pp. 334-338
-
-
Morris, M.1
Gershenson, D.M.2
Wharton, J.T.3
-
12
-
-
0033670096
-
Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer
-
Gadducci A., Iacconi P., Cosio S., et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol. Oncol. 79 (2000) 344-349
-
(2000)
Gynecol. Oncol.
, vol.79
, pp. 344-349
-
-
Gadducci, A.1
Iacconi, P.2
Cosio, S.3
-
13
-
-
0032053575
-
Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma
-
Gelblum D., Mychalczak B., Almadrones L., et al. Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma. Gynecol. Oncol. 69 (1998) 36-41
-
(1998)
Gynecol. Oncol.
, vol.69
, pp. 36-41
-
-
Gelblum, D.1
Mychalczak, B.2
Almadrones, L.3
-
14
-
-
4644285766
-
Tertiary cytoreduction in patients with recurrent ovarian carcinoma
-
Leitao Jr. M.M., Kardos S., Barakat R.R., et al. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol. Oncol. 95 (2004) 181-188
-
(2004)
Gynecol. Oncol.
, vol.95
, pp. 181-188
-
-
Leitao Jr., M.M.1
Kardos, S.2
Barakat, R.R.3
|